Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate

Significance Prostate cancer is an androgen receptor (AR)-dependent disease. Goals in treatment of prostate cancer include keeping low Gleason grades low and preventing development of the lethal disease castration-resistant metastatic prostate cancer. The present study revealed that ERβ modulates AR signaling by repressing AR driver RORc and increasing AR corepressor DACH1/2. Loss of ERβ resulted in up-regulation of genes whose expression is associated with poor prognosis in prostate cancer accompanied by down-regulation of tumor-suppressive or tumor-preventive genes. Treatment of mice with an ERβ agonist resulted in the nuclear import of PTEN and repression of AR signaling. ERβ may be a promising target for treating early stage prostate cancer to prevent cancer progression. As estrogen receptor β−/− (ERβ−/−) mice age, the ventral prostate (VP) develops increased numbers of hyperplastic, fibroplastic lesions and inflammatory cells. To identify genes involved in these changes, we used RNA sequencing and immunohistochemistry to compare gene expression profiles in the VP of young (2-mo-old) and aging (18-mo-old) ERβ−/− mice and their WT littermates. We also treated young and old WT mice with an ERβ-selective agonist and evaluated protein expression. The most significant findings were that ERβ down-regulates androgen receptor (AR) signaling and up-regulates the tumor suppressor phosphatase and tensin homolog (PTEN). ERβ agonist increased expression of the AR corepressor dachshund family (DACH1/2), T-cadherin, stromal caveolin-1, and nuclear PTEN and decreased expression of RAR-related orphan receptor c, Bcl2, inducible nitric oxide synthase, and IL-6. In the ERβ−/− mouse VP, RNA sequencing revealed that the following genes were up-regulated more than fivefold: Bcl2, clusterin, the cytokines CXCL16 and -17, and a marker of basal/intermediate cells (prostate stem cell antigen) and cytokeratins 4, 5, and 17. The most down-regulated genes were the following: the antioxidant gene glutathione peroxidase 3; protease inhibitors WAP four-disulfide core domain 3 (WFDC3); the tumor-suppressive genes T-cadherin and caveolin-1; the regulator of transforming growth factor β signaling SMAD7; and the PTEN ubiquitin ligase NEDD4. The role of ERβ in opposing AR signaling, proliferation, and inflammation suggests that ERβ-selective agonists may be used to prevent progression of prostate cancer, prevent fibrosis and development of benign prostatic hyperplasia, and treat prostatitis.

[1]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[2]  J. Gustafsson,et al.  An ERβ agonist induces browning of subcutaneous abdominal fat pad in obese female mice , 2016, Scientific Reports.

[3]  Motoyasu Ozawa,et al.  Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta. , 2016, Bioorganic & medicinal chemistry.

[4]  T. Friedlander,et al.  Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. , 2016, Urologic oncology.

[5]  S. Koochekpour,et al.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer , 2016, Oncotarget.

[6]  Andrew Brenner,et al.  Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma , 2016, Scientific Reports.

[7]  K. Lam,et al.  ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer , 2016, Nature Medicine.

[8]  R. Pestell,et al.  Endogenous Dach1 in cancer , 2015, Oncoscience.

[9]  M. C. Avellar,et al.  Changes in Estrogen Receptor ERβ (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats , 2015, PloS one.

[10]  J. Gunnersen,et al.  Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity. , 2015, Journal of molecular cell biology.

[11]  B. Katzenellenbogen,et al.  Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model , 2015, Journal of medicinal chemistry.

[12]  J. Katzenellenbogen,et al.  Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential , 2014, Steroids.

[13]  C. Roehrborn,et al.  Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy , 2014, Prostate Cancer and Prostatic Disease.

[14]  J. Gustafsson,et al.  Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer , 2014, Oncogene.

[15]  J. Howitt,et al.  Rab5 and Ndfip1 Are Involved in Pten Ubiquitination and Nuclear Trafficking , 2014, Traffic.

[16]  J. Herman,et al.  Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling , 2014, Journal of cellular and molecular medicine.

[17]  Gioele La Manno,et al.  Quantitative single-cell RNA-seq with unique molecular identifiers , 2013, Nature Methods.

[18]  Shintaro Katayama,et al.  SAMstrt: statistical test for differential expression in single-cell transcriptome with spike-in normalization , 2013, Bioinform..

[19]  J. Gustafsson,et al.  Targeting estrogen receptor β in microglia and T cells to treat experimental autoimmune encephalomyelitis , 2013, Proceedings of the National Academy of Sciences.

[20]  G. Fourel,et al.  The human NUPR1/P8 gene is transcriptionally activated by transforming growth factor β via the SMAD signalling pathway. , 2012, The Biochemical journal.

[21]  M. Frydenberg,et al.  Estrogen Receptor β Activation Impairs Prostatic Regeneration by Inducing Apoptosis in Murine and Human Stem/Progenitor Enriched Cell Populations , 2012, PloS one.

[22]  J. K. Day,et al.  Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice. , 2012, Endocrinology.

[23]  M. Ghosh,et al.  The Chaperone-assisted E3 Ligase C Terminus of Hsc70-interacting Protein (CHIP) Targets PTEN for Proteasomal Degradation* , 2012, The Journal of Biological Chemistry.

[24]  S. Andersson,et al.  Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[25]  D. Rowley,et al.  The functional role of reactive stroma in benign prostatic hyperplasia. , 2011, Differentiation; research in biological diversity.

[26]  J. Gustafsson,et al.  Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity , 2011, Breast Cancer Research.

[27]  A. Andreeva,et al.  Cadherin 13 in cancer , 2010, Genes, chromosomes & cancer.

[28]  I. Leav,et al.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. , 2010, Cancer cell.

[29]  J. Hartman,et al.  Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. , 2009, Cancer research.

[30]  F. Sotgia,et al.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation , 2009, Cell cycle.

[31]  J. Gustafsson,et al.  A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia , 2009, Proceedings of the National Academy of Sciences.

[32]  L. Esserman,et al.  Cost-effectiveness of genetic testing for BRCA1 and BRCA2 mutations. , 2009 .

[33]  Jorge Yao,et al.  Androgen receptor is a tumor suppressor and proliferator in prostate cancer , 2008, Proceedings of the National Academy of Sciences.

[34]  Jon Wakefield,et al.  Gamma Generalized Linear Models for Pharmacokinetic Data , 2008, Biometrics.

[35]  P. Kushner,et al.  Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells , 2008, Breast Cancer Research and Treatment.

[36]  T. I. Richardson,et al.  Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. , 2007, Bioorganic & medicinal chemistry letters.

[37]  Sean R. Dinn,et al.  Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. , 2007, Bioorganic & medicinal chemistry letters.

[38]  J. Gustafsson,et al.  Estrogen receptor β-deficient female mice develop a bladder phenotype resembling human interstitial cystitis , 2007, Proceedings of the National Academy of Sciences.

[39]  Johan Hartman,et al.  Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts , 2006 .

[40]  G. Durst,et al.  Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. , 2006, Journal of Medicinal Chemistry.

[41]  S. Opal,et al.  WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock , 2006, Critical care medicine.

[42]  J. Gustafsson,et al.  Lung dysfunction causes systemic hypoxia in estrogen receptor β knockout (ERβ−/−) mice , 2006 .

[43]  J. Keith,et al.  ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. , 2005, Journal of medicinal chemistry.

[44]  J. Gustafsson,et al.  Estrogen Receptor-Beta Regulates Epithelial Cell Differentiation in the Mouse Ventral Prostate , 2004, Hormone Research in Paediatrics.

[45]  Ruth Etzioni,et al.  Metastases of prostate cancer express estrogen receptor-beta. , 2004, Urology.

[46]  Iwan Gunawan,et al.  Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. , 2004, Journal of medicinal chemistry.

[47]  J. Gustafsson,et al.  Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate , 2004 .

[48]  J. Hartman,et al.  Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D , 2004 .

[49]  Naoya Masumori,et al.  Modulation of phenotype of human prostatic stromal cells by transforming growth factor‐betas , 2004, The Prostate.

[50]  B. Komm,et al.  Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease , 2003 .

[51]  J. Gustafsson,et al.  Disruption of the estrogen receptor β gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Lathe,et al.  An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Fosså,et al.  Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. , 2002, Human pathology.

[54]  J. Gustafsson,et al.  Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor β , 2002, Science.

[55]  J. Gustafsson,et al.  Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer , 2001 .

[56]  J. Gustafsson,et al.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  E. Klein.  An update on prostate cancer. , 1995, Cleveland Clinic journal of medicine.

[59]  Brawer Mk,et al.  Update: prostate cancer. , 1990 .

[60]  J. Gustafsson,et al.  Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Johan Hartman,et al.  Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. , 2006, Cancer research.

[62]  J. Hartman,et al.  Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  B. Komm,et al.  Evaluation of an estrogen receptor-beta agonist in animal models of human disease. , 2003, Endocrinology.

[64]  R. Lathe,et al.  An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Gustafsson,et al.  Frequent loss of estrogen receptor-beta expression in prostate cancer. , 2001, Cancer research.

[66]  G. Mardon,et al.  Molecular and Cellular Pathobiology the Endogenous Cell-fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a Cxcl Signaling Module , 2022 .

[67]  H. Bonkhoff,et al.  Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma , 2003, The Prostate.